Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Unit price / market price
-
$0.9698
-
Total 13F principal
-
$65,515,065
-
Principal change
-
-$34,221,935
-
Total reported value
-
$63,620,509
-
Number of holders
-
23
-
Value change
-
-$33,301,456
-
Number of buys
-
8
-
Number of sells
-
9
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q3 2022
As of 30 Sep 2022 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 had 23 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $65,515,065 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included OAKTREE CAPITAL MANAGEMENT LP, CAPSTONE INVESTMENT ADVISORS, LLC, PALISADE CAPITAL MANAGEMENT LLC/NJ, Voya Investment Management LLC, JPMORGAN CHASE & CO, Russell Investments Group, Ltd., Radcliffe Capital Management, L.P., SCHRODER INVESTMENT MANAGEMENT GROUP, TORONTO DOMINION BANK, and WESTWOOD HOLDINGS GROUP INC.
This table shows 23 bond principal holders of the security as of 30 Sep 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.